Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Glycanova AS
AS
Active
Org 994035495
Øraveien 2, 1630
Gamle Fredrikstad
Manufacture of pharmaceutical preparations
·
NACE 2120
Est. 2009 · 17 years old
3 employees
Monitor
Share
Norway
/
Companies
/
Manufacture of pharmaceutical preparations
/
Glycanova AS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
NOK millions
5M
4M
2M
1M
0M
2020: 4M
4M
2020
2021: 2M (-50% vs 2020)
2M
-50%
2021
2022: 3M (+50% vs 2021)
3M
+50%
2022
2023: 1M (-67% vs 2022)
1M
-67%
2023
2024: 1M (0% vs 2023)
1M
0%
2024
EBITDA
NOK millions
7M
3M
0M
-3M
-7M
2020: 4M
4M
2020
2021: -2M (-150% vs 2020)
-2M
-150%
2021
2022: -4M (-100% vs 2021)
-4M
-100%
2022
2023: -3M (+25% vs 2022)
-3M
+25%
2023
2024: -1M (+67% vs 2023)
-1M
+67%
2024
Income statement
NOK thousands
Item
2024
2023
2022
2021
2020
Revenue
1 405
1 009
2 573
2 200
3 975
Staff expenses
−1 483
−1 110
−3 046
−1 992
3 501
EBITDA
−947
−2 756
−3 525
−2 412
4 499
Depreciation & amort.
−105
−167
−353
−353
−150
EBIT
−1 053
−2 923
−3 877
−2 765
4 349
Net financials
−10
14
−20
−70
11
Profit before tax
−1 062
−2 910
−3 898
−2 835
4 360
Tax
−0
−0
−0
−0
−0
Net profit
−1 062
−2 910
−3 898
−2 835
4 360
Balance sheet
NOK thousands
Item
2024
2023
2022
2021
2020
Total assets
941
619
1 614
4 420
2 495
Equity
−2 461
−2 274
−372
3 526
−1 108
Long-term debt
0
0
0
0
0
Short-term debt
3 402
2 892
1 985
894
3 603
Total debt
3 402
2 892
1 985
894
3 603
Financial ratios
5-year trend
EBITDA margin
−67,4 %
This company
15,8 %
Market median
This company
Market median
527% below market
2020
2024
Equity ratio
−261,5 %
This company
38,2 %
Market median
This company
Market median
785% below market
2020
2024
Return on equity
—
This company
18,4 %
Market median
This company
Market median
2020
2024
Net profit margin
−75,6 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2020
2024
Asset turnover
1,49×
This company
1,12×
Market median
This company
Market median
33% above market
2020
2024
Debt / equity
—
This company
0,62×
Market median
This company
Market median
2020
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
View
PDF
More on Glycanova AS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
